Table 2.
Association of lncRNA MSC-AS1 expression with clinical pathological characteristics by logistic regression.
| Characteristics | Odds ratio in MSC-AS1 expression | Odds ratio (OR) | P -value |
|---|---|---|---|
| T stage (T3 and T4 vs. T1 and T2) | 367 | 2.25 (1.40–3.67) | <0.001 |
| N stage (N1 and N2 and N3 vs. N0) | 357 | 1.20 (0.76–1.88) | 0.435 |
| M stage (M1 vs. M0) | 355 | 0.93 (0.41–2.12) | 0.870 |
| Pathologic stage (Stage III and Stage IV vs. Stage I and Stage II) | 352 | 1.32 (0.87–2.02) | 0.190 |
| Histological type (diffuse type vs. tubular type) | 132 | 5.28 (2.54–11.37) | <0.001 |
| Histologic grade (G3 vs. G1 and G2) | 366 | 3.09 (2.01–4.82) | <0.001 |
| Primary therapy outcome (CR vs. PD and SD and PR) | 317 | 1.14 (0.69–1.88) | 0.604 |
| Residual tumor (R1 and R2 vs. R0) | 329 | 1.19 (0.56–2.51) | 0.649 |
| TP53 status (Mut vs. WT) | 372 | 0.55 (0.37–0.84) | 0.005 |
| PIK3CA status (Mut vs. WT) | 372 | 0.55 (0.30–0.96) | 0.039 |